Targeted‐nanoliposomal combretastatin A4 (CA‐4) as an efficient antivascular candidate in the metastatic cancer treatment
A number of antiangiogenic drugs have been approved by the Food and Drug Administration which are used in cancer therapy, and variety of other agents in several stages of clinical development or in preclinical assessment. Among these, combretastatin A4 (CA‐4) is an under‐researched inhibitor of angi...
Saved in:
| Published in | Journal of cellular physiology Vol. 234; no. 9; pp. 14721 - 14733 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Wiley Subscription Services, Inc
01.09.2019
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | A number of antiangiogenic drugs have been approved by the Food and Drug Administration which are used in cancer therapy, and variety of other agents in several stages of clinical development or in preclinical assessment. Among these, combretastatin A4 (CA‐4) is an under‐researched inhibitor of angiogenesis that shows potential activity in the treatment of advanced tumors with migration capacity. However, its clinical application has been limited due to poor water solubility, low bioavailability, rapid metabolism, and systemic elimination. During the last decade, numerous investigations have been done to overcome these problems by using different CA‐4 delivery systems or developing produgs of CA‐4 or its structural analogs. Nevertheless, these strategies could not be efficient out of the undesired side effects on normal tissues. Nanoliposomal CA‐4 not only benefits from the advantage of using liposomal drugs as opposed to free drugs but also can accumulate in the tumor site via specific targeting ligands, which leads to efficient targeting and enhancement of bioavailability. To the best of our knowledge, we consider an important attempt to understand different factors that might influence the CA‐4 loading and release pattern of liposomes and the consequent results in tumor therapy. In this review, we shed light on various studied liposomal CA‐4 formulations showing application thereof in cancer treatment.
In this review, we shed light on various studied liposomal combretastatin A4 (CA‐4) formulations showing application thereof in cancer treatment. |
|---|---|
| AbstractList | Abstract A number of antiangiogenic drugs have been approved by the Food and Drug Administration which are used in cancer therapy, and variety of other agents in several stages of clinical development or in preclinical assessment. Among these, combretastatin A4 (CA‐4) is an under‐researched inhibitor of angiogenesis that shows potential activity in the treatment of advanced tumors with migration capacity. However, its clinical application has been limited due to poor water solubility, low bioavailability, rapid metabolism, and systemic elimination. During the last decade, numerous investigations have been done to overcome these problems by using different CA‐4 delivery systems or developing produgs of CA‐4 or its structural analogs. Nevertheless, these strategies could not be efficient out of the undesired side effects on normal tissues. Nanoliposomal CA‐4 not only benefits from the advantage of using liposomal drugs as opposed to free drugs but also can accumulate in the tumor site via specific targeting ligands, which leads to efficient targeting and enhancement of bioavailability. To the best of our knowledge, we consider an important attempt to understand different factors that might influence the CA‐4 loading and release pattern of liposomes and the consequent results in tumor therapy. In this review, we shed light on various studied liposomal CA‐4 formulations showing application thereof in cancer treatment. A number of antiangiogenic drugs have been approved by the Food and Drug Administration which are used in cancer therapy, and variety of other agents in several stages of clinical development or in preclinical assessment. Among these, combretastatin A4 (CA‐4) is an under‐researched inhibitor of angiogenesis that shows potential activity in the treatment of advanced tumors with migration capacity. However, its clinical application has been limited due to poor water solubility, low bioavailability, rapid metabolism, and systemic elimination. During the last decade, numerous investigations have been done to overcome these problems by using different CA‐4 delivery systems or developing produgs of CA‐4 or its structural analogs. Nevertheless, these strategies could not be efficient out of the undesired side effects on normal tissues. Nanoliposomal CA‐4 not only benefits from the advantage of using liposomal drugs as opposed to free drugs but also can accumulate in the tumor site via specific targeting ligands, which leads to efficient targeting and enhancement of bioavailability. To the best of our knowledge, we consider an important attempt to understand different factors that might influence the CA‐4 loading and release pattern of liposomes and the consequent results in tumor therapy. In this review, we shed light on various studied liposomal CA‐4 formulations showing application thereof in cancer treatment. A number of antiangiogenic drugs have been approved by the Food and Drug Administration which are used in cancer therapy, and variety of other agents in several stages of clinical development or in preclinical assessment. Among these, combretastatin A4 (CA‐4) is an under‐researched inhibitor of angiogenesis that shows potential activity in the treatment of advanced tumors with migration capacity. However, its clinical application has been limited due to poor water solubility, low bioavailability, rapid metabolism, and systemic elimination. During the last decade, numerous investigations have been done to overcome these problems by using different CA‐4 delivery systems or developing produgs of CA‐4 or its structural analogs. Nevertheless, these strategies could not be efficient out of the undesired side effects on normal tissues. Nanoliposomal CA‐4 not only benefits from the advantage of using liposomal drugs as opposed to free drugs but also can accumulate in the tumor site via specific targeting ligands, which leads to efficient targeting and enhancement of bioavailability. To the best of our knowledge, we consider an important attempt to understand different factors that might influence the CA‐4 loading and release pattern of liposomes and the consequent results in tumor therapy. In this review, we shed light on various studied liposomal CA‐4 formulations showing application thereof in cancer treatment. In this review, we shed light on various studied liposomal combretastatin A4 (CA‐4) formulations showing application thereof in cancer treatment. |
| Author | Zamani, Parvin Jaafari, Mahmoud Reza Malaekeh‐Nikouei, Bizhan Iranshahi, Mehrdad Momtazi‐Borojeni, Amir Abbas Navashenaq, Jamshid Gholizadeh Nik, Maryam Ebrahimi |
| Author_xml | – sequence: 1 givenname: Maryam Ebrahimi surname: Nik fullname: Nik, Maryam Ebrahimi organization: Student Research Committee, Mashhad University of Medical Sciences – sequence: 2 givenname: Amir Abbas orcidid: 0000-0002-4376-1083 surname: Momtazi‐Borojeni fullname: Momtazi‐Borojeni, Amir Abbas organization: Faculty of Medicine, Mashhad University of Medical Sciences – sequence: 3 givenname: Parvin surname: Zamani fullname: Zamani, Parvin organization: Faculty of Medicine, Mashhad University of Medical Sciences – sequence: 4 givenname: Jamshid Gholizadeh surname: Navashenaq fullname: Navashenaq, Jamshid Gholizadeh organization: Immunology Research Center, School of Medicine, Mashhad University of Medical Sciences – sequence: 5 givenname: Mehrdad surname: Iranshahi fullname: Iranshahi, Mehrdad organization: Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences – sequence: 6 givenname: Mahmoud Reza orcidid: 0000-0003-3908-6828 surname: Jaafari fullname: Jaafari, Mahmoud Reza organization: School of Pharmacy, Mashhad University of Medical Sciences – sequence: 7 givenname: Bizhan orcidid: 0000-0002-1908-9530 surname: Malaekeh‐Nikouei fullname: Malaekeh‐Nikouei, Bizhan email: Malaekehb@mums.ac.ir organization: Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30697744$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kc9u1DAQhy1URLcLB14AWeLSHtKO7ThZH1cr_qoSHMo5GjtjyCpxFttb1AMSj8Az8iR42ZYDEqfRaL75NJrfGTsJcyDGngu4FADyaut2l3IlFTxiCwGmrepGyxO2KDNRGV2LU3aW0hYAjFHqCTtV0Ji2resF-36D8TNl6n_9-BkwzOOwm9M84cjdPNlIGVPGPAS-rvn5Zl2o-oJj4hg4eT-4gUIuTR5uMbn9iJE7DP3QYyZetvIX4tODxB1mjiLPkTBPZfMpe-xxTPTsvi7Zp9evbjZvq-sPb95t1teVU1pBZbVqlbCt8uQ8NI32wvYtAmivV1aQtU0vPTbgJBgE2UCtvbdolKitIaWW7Pzo3cX5655S7qYhORpHDDTvUydFa7SUhx8u2ct_0O28j6Fc1xXArDSYRhTq4ki5OKcUyXe7OEwY7zoB3SGTrmTS_cmksC_ujXs7Uf-XfAihAFdH4Nsw0t3_Td37zcej8jcB_5m_ |
| CitedBy_id | crossref_primary_10_1002_iub_2458 crossref_primary_10_1016_j_ejphar_2021_174419 crossref_primary_10_3390_pharmaceutics15041282 crossref_primary_10_1002_ddr_22016 crossref_primary_10_1038_s41598_023_43689_4 crossref_primary_10_1007_s12032_023_02197_1 crossref_primary_10_1002_bab_2275 crossref_primary_10_1016_j_ijpharm_2021_120710 crossref_primary_10_1007_s10637_024_01440_4 crossref_primary_10_1016_j_ijpharm_2021_121396 crossref_primary_10_1016_j_pbiomolbio_2021_04_001 crossref_primary_10_2174_1871520623666230411152115 crossref_primary_10_1016_j_pbiomolbio_2022_04_002 crossref_primary_10_1016_j_pbiomolbio_2023_04_006 crossref_primary_10_2174_1567201819666220209093443 crossref_primary_10_1016_j_ejphar_2020_173692 crossref_primary_10_1039_D0BM00713G crossref_primary_10_3390_ma14041025 crossref_primary_10_1039_C8CS01021H crossref_primary_10_1039_D4NA00079J |
| Cites_doi | 10.1158/1078-0432.CCR-0642-03 10.1016/j.jconrel.2014.05.028 10.1159/000488087 10.1016/j.ijpharm.2013.10.018 10.1016/S0168-3659(01)00309-1 10.1211/0022357011778016 10.3109/08982104.2013.770017 10.1016/j.colsurfb.2009.07.024 10.1016/j.ijpharm.2018.09.047 10.1021/bi950414i 10.18632/oncotarget.3613 10.18632/oncotarget.9889 10.1074/jbc.274.17.11721 10.1016/S0076-6879(04)87003-4 10.1016/j.jconrel.2014.10.012 10.1055/s-0032-1328363 10.1016/j.biomaterials.2013.05.081 10.1016/S0092-8674(00)81010-7 10.1016/S1773-2247(09)50007-X 10.1016/j.mce.2007.12.002 10.1007/s11095-009-9826-1 10.1038/nm0195-27 10.1016/j.biomaterials.2014.11.003 10.1016/j.addr.2003.10.029 10.1042/bj1860591 10.1139/v82-202 10.1016/0024-3205(82)90087-X 10.1006/excr.1997.3844 10.1016/S0006-291X(75)80180-X 10.1016/S0959-8049(00)00029-0 10.1002/(SICI)1097-4636(199908)46:2<141::AID-JBM2>3.0.CO;2-U 10.1016/0005-2736(94)90003-5 10.1016/j.biomaterials.2010.05.075 10.2174/187152010794728639 10.1007/978-1-60327-360-2_2 10.1016/j.nano.2011.05.003 10.1016/j.nano.2009.02.001 10.1016/j.ijpharm.2014.09.055 10.1016/j.ejpb.2013.12.003 10.1016/j.jconrel.2012.06.002 10.1016/S0006-3495(90)82444-9 10.1172/JCI24586 10.1172/JCI118997 10.1126/science.1095833 10.1007/978-3-642-00477-3_2 10.2165/00003088-200342050-00002 10.1007/s11095-014-1515-z 10.1016/j.jconrel.2010.10.027 10.2174/138955707782795647 10.1016/j.drup.2005.10.002 10.1161/01.ATV.15.8.1229 10.1016/S0076-6879(07)26020-3 10.1128/AAC.01319-08 10.1016/S0006-3495(98)77849-X 10.2174/156720105774370159 10.1208/pt070232 10.2174/1566524033479465 10.1016/j.colsurfb.2008.09.001 10.1038/srep02534 10.1016/0026-0495(90)90217-Z 10.1016/0304-4165(79)90412-4 10.1089/105072502321085153 10.1038/nature04483 10.1038/35025220 10.1016/S0360-3016(98)00299-5 10.1073/pnas.96.17.9815 10.1517/13543784.13.9.1171 10.1038/sj.bjc.6603694 10.1007/s11095-012-0797-2 10.1016/S1748-0132(08)70015-X 10.1172/JCI118870 10.1038/sj.bjc.6692174 10.1007/s11095-005-5646-0 10.1021/mp9000662 10.1097/00001813-200101000-00008 10.1016/j.jconrel.2005.03.030 10.1038/nature10144 10.1517/17425247.5.1.25 10.1016/S0169-409X(97)00083-5 10.1007/s11172-010-0390-y 10.1111/j.1476-5381.2009.00112.x 10.1007/s11095-010-0184-9 10.1016/j.ejpb.2010.01.002 |
| ContentType | Journal Article |
| Copyright | 2019 Wiley Periodicals, Inc. |
| Copyright_xml | – notice: 2019 Wiley Periodicals, Inc. |
| DBID | NPM AAYXX CITATION 7TK 7U7 8FD C1K FR3 K9. P64 RC3 7X8 |
| DOI | 10.1002/jcp.28230 |
| DatabaseName | PubMed CrossRef Neurosciences Abstracts Toxicology Abstracts Technology Research Database Environmental Sciences and Pollution Management Engineering Research Database ProQuest Health & Medical Complete (Alumni) Biotechnology and BioEngineering Abstracts Genetics Abstracts MEDLINE - Academic |
| DatabaseTitle | PubMed CrossRef Genetics Abstracts Technology Research Database Toxicology Abstracts ProQuest Health & Medical Complete (Alumni) Engineering Research Database Neurosciences Abstracts Biotechnology and BioEngineering Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
| DatabaseTitleList | CrossRef Genetics Abstracts PubMed |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Anatomy & Physiology Biology |
| EISSN | 1097-4652 |
| EndPage | 14733 |
| ExternalDocumentID | 10_1002_jcp_28230 30697744 JCP28230 |
| Genre | reviewArticle Journal Article Review |
| GrantInformation_xml | – fundername: Mashhad University of Medical Sciences |
| GroupedDBID | --- -DZ -~X .3N .55 .GA .GJ .Y3 05W 0R~ 10A 1L6 1OB 1OC 1ZS 31~ 33P 36B 3O- 3SF 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52S 52T 52U 52W 52X 53G 5GY 5RE 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 85S 8UM 930 9M8 A03 AAESR AAEVG AAHHS AANLZ AAONW AASGY AAXRX AAZKR ABCQN ABCUV ABEFU ABEML ABIJN ABJNI ABPPZ ABPVW ACAHQ ACBWZ ACCFJ ACCZN ACGFO ACGFS ACNCT ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AETEA AEUQT AEUYR AFBPY AFFPM AFGKR AFPWT AFRAH AFZJQ AHBTC AHMBA AIAGR AITYG AIURR AIWBW AJBDE AJXKR ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ATUGU AUFTA AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMNLL BMXJE BNHUX BQCPF BROTX BRXPI BY8 CS3 D-E D-F DCZOG DPXWK DR1 DR2 DRFUL DRSTM DU5 EBD EBS EJD EMB EMOBN F00 F01 F04 F5P FEDTE G-S G.N G8K GNP GODZA H.T H.X HBH HF~ HGLYW HHY HHZ HVGLF HZ~ H~9 IH2 IX1 J0M JPC KQQ L7B LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES M56 MEWTI MK4 MRFUL MRSTM MSFUL MSSTM MVM MXFUL MXSTM N04 N05 N9A NEJ NF~ NNB O66 O9- OHT OIG P2P P2W P2X P4D PALCI PQQKQ Q.N Q11 QB0 QRW R.K RIWAO ROL RWI RWR RX1 RYL S10 SAMSI SUPJJ SV3 TN5 TWZ UB1 UPT V2E V8K VQP W8V W99 WBKPD WH7 WIB WIH WIK WJL WNSPC WOHZO WQJ WRC WXSBR WYB WYISQ X7M XG1 XJT XOL XPP XSW XV2 Y6R YQT YZZ ZGI ZXP ZZTAW ~IA ~WT NPM AAYXX CITATION 7TK 7U7 8FD C1K FR3 K9. P64 RC3 7X8 |
| ID | FETCH-LOGICAL-c3530-b53731b73fecf0665f1bd7a005f58b1ebb6d2fa60c209a026045ffba9314b9e33 |
| IEDL.DBID | DR2 |
| ISSN | 0021-9541 |
| IngestDate | Fri Aug 16 22:52:31 EDT 2024 Thu Oct 10 20:57:36 EDT 2024 Thu Sep 26 20:57:09 EDT 2024 Sat Sep 28 08:17:00 EDT 2024 Sat Aug 24 01:17:55 EDT 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 9 |
| Keywords | nanoliposome cancer antiangiogenesis combretastatin A4 |
| Language | English |
| License | 2019 Wiley Periodicals, Inc. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c3530-b53731b73fecf0665f1bd7a005f58b1ebb6d2fa60c209a026045ffba9314b9e33 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 |
| ORCID | 0000-0002-4376-1083 0000-0003-3908-6828 0000-0002-1908-9530 |
| PMID | 30697744 |
| PQID | 2229850961 |
| PQPubID | 1006363 |
| PageCount | 13 |
| ParticipantIDs | proquest_miscellaneous_2179522282 proquest_journals_2229850961 crossref_primary_10_1002_jcp_28230 pubmed_primary_30697744 wiley_primary_10_1002_jcp_28230_JCP28230 |
| PublicationCentury | 2000 |
| PublicationDate | September 2019 2019-Sep 2019-09-00 20190901 |
| PublicationDateYYYYMMDD | 2019-09-01 |
| PublicationDate_xml | – month: 09 year: 2019 text: September 2019 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Hoboken |
| PublicationTitle | Journal of cellular physiology |
| PublicationTitleAlternate | J Cell Physiol |
| PublicationYear | 2019 |
| Publisher | Wiley Subscription Services, Inc |
| Publisher_xml | – name: Wiley Subscription Services, Inc |
| References | e_1_2_11_1_100_1 e_1_2_11_1_93_1 Malcontenti‐Wilson C. (e_1_2_11_1_56_1) 2001; 7 e_1_2_11_1_74_1 e_1_2_11_1_97_1 e_1_2_11_1_29_1 e_1_2_11_1_21_1 e_1_2_11_1_44_1 e_1_2_11_1_67_1 e_1_2_11_1_40_1 e_1_2_11_1_63_1 e_1_2_11_1_82_1 Dark G. G. (e_1_2_11_1_20_1) 1997; 57 e_1_2_11_1_86_1 e_1_2_11_1_17_1 e_1_2_11_1_8_1 e_1_2_11_1_13_1 e_1_2_11_1_36_1 e_1_2_11_1_55_1 e_1_2_11_1_32_1 e_1_2_11_1_51_1 e_1_2_11_1_90_1 e_1_2_11_1_71_1 e_1_2_11_1_94_1 e_1_2_11_1_101_1 e_1_2_11_1_75_1 e_1_2_11_1_79_1 e_1_2_11_1_49_1 e_1_2_11_1_26_1 e_1_2_11_1_68_1 e_1_2_11_1_45_1 e_1_2_11_1_22_1 e_1_2_11_1_64_1 e_1_2_11_1_41_1 e_1_2_11_1_60_1 e_1_2_11_1_83_1 Moiseeva E. (e_1_2_11_1_59_1) 2011; 5 e_1_2_11_1_87_1 e_1_2_11_1_18_1 e_1_2_11_1_5_1 e_1_2_11_1_14_1 e_1_2_11_1_37_1 e_1_2_11_1_9_1 Drummond D. C. (e_1_2_11_1_25_1) 1999; 51 e_1_2_11_1_10_1 e_1_2_11_1_33_1 e_1_2_11_1_91_1 Lasic D. D. (e_1_2_11_1_48_1) 1998 e_1_2_11_1_72_1 e_1_2_11_1_95_1 e_1_2_11_1_76_1 e_1_2_11_1_99_1 e_1_2_11_1_27_1 e_1_2_11_1_46_1 e_1_2_11_1_23_1 e_1_2_11_1_42_1 e_1_2_11_1_65_1 Nallamothu R. (e_1_2_11_1_62_1) 2006; 60 e_1_2_11_1_61_1 Zhang M. (e_1_2_11_1_98_1) 2011; 6 Malaekeh‐Nikouei B. (e_1_2_11_1_53_1) 2007; 15 Amanolahi F. (e_1_2_11_1_4_1) 2018; 5 Su M. (e_1_2_11_1_78_1) 2016; 6 e_1_2_11_1_80_1 e_1_2_11_1_88_1 Lin C. M. (e_1_2_11_1_50_1) 1988; 34 e_1_2_11_1_2_1 e_1_2_11_1_19_1 e_1_2_11_1_38_1 e_1_2_11_1_6_1 e_1_2_11_1_15_1 Pettit G. R. (e_1_2_11_1_69_1) 1995; 10 e_1_2_11_1_11_1 e_1_2_11_1_30_1 Tozer G. M. (e_1_2_11_1_84_1) 1999; 59 Ramezani M. (e_1_2_11_1_70_1) 2011; 14 e_1_2_11_1_92_1 Malaekeh‐Nikouei B. (e_1_2_11_1_52_1) 2011; 6 e_1_2_11_1_73_1 e_1_2_11_1_96_1 e_1_2_11_1_77_1 e_1_2_11_1_28_1 e_1_2_11_1_24_1 e_1_2_11_1_47_1 e_1_2_11_1_66_1 Forssen E. A. (e_1_2_11_1_34_1) 1992; 52 e_1_2_11_1_43_1 e_1_2_11_1_81_1 e_1_2_11_1_85_1 e_1_2_11_1_89_1 e_1_2_11_1_39_1 e_1_2_11_1_3_1 e_1_2_11_1_16_1 e_1_2_11_1_35_1 e_1_2_11_1_58_1 e_1_2_11_1_7_1 e_1_2_11_1_12_1 e_1_2_11_1_31_1 e_1_2_11_1_54_1 Mansury D. (e_1_2_11_1_57_1) 2019; 7 |
| References_xml | – ident: e_1_2_11_1_81_1 doi: 10.1158/1078-0432.CCR-0642-03 – ident: e_1_2_11_1_90_1 doi: 10.1016/j.jconrel.2014.05.028 – ident: e_1_2_11_1_101_1 doi: 10.1159/000488087 – ident: e_1_2_11_1_5_1 doi: 10.1016/j.ijpharm.2013.10.018 – ident: e_1_2_11_1_51_1 doi: 10.1016/S0168-3659(01)00309-1 – volume: 15 start-page: 176 issue: 3 year: 2007 ident: e_1_2_11_1_53_1 article-title: Preparation, characterization and mucoadhesive evaluation of chitosan coated liposomes containing cyclosporine A. Saudi publication-title: Pharmaceutical Journal contributor: fullname: Malaekeh‐Nikouei B. – ident: e_1_2_11_1_47_1 doi: 10.1211/0022357011778016 – ident: e_1_2_11_1_21_1 doi: 10.3109/08982104.2013.770017 – ident: e_1_2_11_1_6_1 doi: 10.1016/j.colsurfb.2009.07.024 – ident: e_1_2_11_1_28_1 doi: 10.1016/j.ijpharm.2018.09.047 – ident: e_1_2_11_1_75_1 doi: 10.1021/bi950414i – ident: e_1_2_11_1_17_1 doi: 10.18632/oncotarget.3613 – ident: e_1_2_11_1_42_1 doi: 10.18632/oncotarget.9889 – ident: e_1_2_11_1_23_1 doi: 10.1074/jbc.274.17.11721 – ident: e_1_2_11_1_77_1 doi: 10.1016/S0076-6879(04)87003-4 – ident: e_1_2_11_1_89_1 doi: 10.1016/j.jconrel.2014.10.012 – ident: e_1_2_11_1_71_1 doi: 10.1055/s-0032-1328363 – ident: e_1_2_11_1_91_1 doi: 10.1016/j.biomaterials.2013.05.081 – volume: 14 start-page: 82 issue: 1 year: 2011 ident: e_1_2_11_1_70_1 article-title: The effect of linear PEI on characteristics and transfection efficiency of PEI‐based cationic nanoliposomes publication-title: Iranian Journal of Basic Medical Sciences contributor: fullname: Ramezani M. – ident: e_1_2_11_1_14_1 doi: 10.1016/S0092-8674(00)81010-7 – ident: e_1_2_11_1_46_1 doi: 10.1016/S1773-2247(09)50007-X – ident: e_1_2_11_1_87_1 doi: 10.1016/j.mce.2007.12.002 – ident: e_1_2_11_1_66_1 doi: 10.1007/s11095-009-9826-1 – ident: e_1_2_11_1_31_1 doi: 10.1038/nm0195-27 – ident: e_1_2_11_1_99_1 doi: 10.1016/j.biomaterials.2014.11.003 – ident: e_1_2_11_1_27_1 doi: 10.1016/j.addr.2003.10.029 – ident: e_1_2_11_1_45_1 doi: 10.1042/bj1860591 – ident: e_1_2_11_1_68_1 doi: 10.1139/v82-202 – volume: 59 start-page: 1626 issue: 7 year: 1999 ident: e_1_2_11_1_84_1 article-title: Combretastatin A‐4 phosphate as a tumor vascular‐targeting agent publication-title: Cancer Research contributor: fullname: Tozer G. M. – ident: e_1_2_11_1_8_1 doi: 10.1016/0024-3205(82)90087-X – ident: e_1_2_11_1_7_1 doi: 10.1006/excr.1997.3844 – volume-title: Medical applications of liposomes year: 1998 ident: e_1_2_11_1_48_1 contributor: fullname: Lasic D. D. – ident: e_1_2_11_1_37_1 doi: 10.1016/S0006-291X(75)80180-X – volume: 60 start-page: 144 issue: 3 year: 2006 ident: e_1_2_11_1_62_1 article-title: A targeted liposome delivery system for combretastatin A4: Formulation optimization through drug loading and in vitro release studies publication-title: PDA Journal of Pharmaceutical Science and Technology contributor: fullname: Nallamothu R. – volume: 6 start-page: 2337 year: 2011 ident: e_1_2_11_1_98_1 article-title: Multifunctional dendrimer/combretastatin A4 inclusion complexes enable in vitro targeted cancer therapy publication-title: International Journal of Nanomedicine contributor: fullname: Zhang M. – ident: e_1_2_11_1_86_1 doi: 10.1016/S0959-8049(00)00029-0 – ident: e_1_2_11_1_9_1 doi: 10.1002/(SICI)1097-4636(199908)46:2<141::AID-JBM2>3.0.CO;2-U – ident: e_1_2_11_1_83_1 doi: 10.1016/0005-2736(94)90003-5 – ident: e_1_2_11_1_94_1 doi: 10.1016/j.biomaterials.2010.05.075 – volume: 6 start-page: 1 issue: 4 year: 2011 ident: e_1_2_11_1_52_1 article-title: Preparation and characterization of liposomes encapsulated with clindamycin and tretinoin publication-title: IJCP contributor: fullname: Malaekeh‐Nikouei B. – ident: e_1_2_11_1_58_1 doi: 10.2174/187152010794728639 – ident: e_1_2_11_1_60_1 doi: 10.1007/978-1-60327-360-2_2 – ident: e_1_2_11_1_96_1 doi: 10.1016/j.nano.2011.05.003 – ident: e_1_2_11_1_55_1 doi: 10.1016/j.nano.2009.02.001 – ident: e_1_2_11_1_79_1 doi: 10.1016/j.ijpharm.2014.09.055 – ident: e_1_2_11_1_24_1 doi: 10.1016/j.ejpb.2013.12.003 – ident: e_1_2_11_1_49_1 doi: 10.1016/j.jconrel.2012.06.002 – volume: 10 start-page: 299 issue: 4 year: 1995 ident: e_1_2_11_1_69_1 article-title: Antineoplastic agents 322. synthesis of combretastatin A‐4 prodrugs publication-title: Anti‐Cancer Drug Design contributor: fullname: Pettit G. R. – ident: e_1_2_11_1_64_1 doi: 10.1016/S0006-3495(90)82444-9 – ident: e_1_2_11_1_85_1 doi: 10.1172/JCI24586 – volume: 57 start-page: 1829 issue: 10 year: 1997 ident: e_1_2_11_1_20_1 article-title: Combretastatin A‐4, an agent that displays potent and selective toxicity toward tumor vasculature publication-title: Cancer Research contributor: fullname: Dark G. G. – volume: 34 start-page: 200 issue: 2 year: 1988 ident: e_1_2_11_1_50_1 article-title: Interactions of tubulin with potent natural and synthetic analogs of the antimitotic agent combretastatin: A structure‐activity study publication-title: Molecular Pharmacology contributor: fullname: Lin C. M. – ident: e_1_2_11_1_22_1 doi: 10.1172/JCI118997 – ident: e_1_2_11_1_3_1 doi: 10.1126/science.1095833 – ident: e_1_2_11_1_2_1 doi: 10.1007/978-3-642-00477-3_2 – ident: e_1_2_11_1_35_1 doi: 10.2165/00003088-200342050-00002 – ident: e_1_2_11_1_88_1 doi: 10.1007/s11095-014-1515-z – ident: e_1_2_11_1_92_1 doi: 10.1016/j.jconrel.2010.10.027 – ident: e_1_2_11_1_16_1 doi: 10.2174/138955707782795647 – ident: e_1_2_11_1_80_1 doi: 10.1016/j.drup.2005.10.002 – ident: e_1_2_11_1_11_1 doi: 10.1161/01.ATV.15.8.1229 – volume: 7 start-page: 156 issue: 2 year: 2019 ident: e_1_2_11_1_57_1 article-title: Increasing cellular immune response in liposomal formulations of DOTAP encapsulated by fusion protein Hspx, PPE44, and Esxv, as a potential tuberculosis vaccine candidate publication-title: Reports of Biochemistry and Molecular Biology contributor: fullname: Mansury D. – ident: e_1_2_11_1_39_1 doi: 10.1016/S0076-6879(07)26020-3 – ident: e_1_2_11_1_43_1 doi: 10.1128/AAC.01319-08 – ident: e_1_2_11_1_82_1 doi: 10.1016/S0006-3495(98)77849-X – ident: e_1_2_11_1_74_1 doi: 10.2174/156720105774370159 – ident: e_1_2_11_1_63_1 doi: 10.1208/pt070232 – ident: e_1_2_11_1_32_1 doi: 10.2174/1566524033479465 – ident: e_1_2_11_1_54_1 doi: 10.1016/j.colsurfb.2008.09.001 – ident: e_1_2_11_1_36_1 doi: 10.1038/srep02534 – ident: e_1_2_11_1_73_1 doi: 10.1016/0026-0495(90)90217-Z – ident: e_1_2_11_1_44_1 doi: 10.1016/0304-4165(79)90412-4 – ident: e_1_2_11_1_26_1 doi: 10.1089/105072502321085153 – ident: e_1_2_11_1_30_1 doi: 10.1038/nature04483 – ident: e_1_2_11_1_12_1 doi: 10.1038/35025220 – volume: 7 start-page: 1052 issue: 4 year: 2001 ident: e_1_2_11_1_56_1 article-title: Combretastatin A4 prodrug study of effect on the growth and the microvasculature of colorectal liver metastases in a murine model publication-title: Clinical Cancer Research contributor: fullname: Malcontenti‐Wilson C. – ident: e_1_2_11_1_41_1 doi: 10.1016/S0360-3016(98)00299-5 – ident: e_1_2_11_1_18_1 doi: 10.1073/pnas.96.17.9815 – ident: e_1_2_11_1_97_1 doi: 10.1517/13543784.13.9.1171 – ident: e_1_2_11_1_40_1 doi: 10.1038/sj.bjc.6603694 – ident: e_1_2_11_1_19_1 doi: 10.1007/s11095-012-0797-2 – ident: e_1_2_11_1_10_1 doi: 10.1016/S1748-0132(08)70015-X – ident: e_1_2_11_1_15_1 doi: 10.1172/JCI118870 – ident: e_1_2_11_1_38_1 doi: 10.1038/sj.bjc.6692174 – ident: e_1_2_11_1_65_1 doi: 10.1007/s11095-005-5646-0 – volume: 6 start-page: 6 year: 2016 ident: e_1_2_11_1_78_1 article-title: The anti‐angiogenic effect and novel mechanisms of action of Combretastatin A‐4 publication-title: Scientific Reports contributor: fullname: Su M. – volume: 52 start-page: 3255 issue: 12 year: 1992 ident: e_1_2_11_1_34_1 article-title: Selective in vivo localization of daunorubicin small unilamellar vesicles in solid tumors publication-title: Cancer Research contributor: fullname: Forssen E. A. – ident: e_1_2_11_1_67_1 doi: 10.1021/mp9000662 – volume: 5 start-page: 276 issue: 3 year: 2011 ident: e_1_2_11_1_59_1 article-title: Liposome formulations of combretastatin A4 and its 4‐arylcoumarin analogue prodrugs: The antitumor effect in the mouse model of breast cancer publication-title: Biomedical Chemistry contributor: fullname: Moiseeva E. – ident: e_1_2_11_1_61_1 doi: 10.1097/00001813-200101000-00008 – ident: e_1_2_11_1_95_1 doi: 10.1016/j.jconrel.2005.03.030 – volume: 5 start-page: 235 issue: 4 year: 2018 ident: e_1_2_11_1_4_1 article-title: Curcumin improved liposomal mitomycin‐induced cell toxicity in bladder cancer cell publication-title: Nanomedicine Journal contributor: fullname: Amanolahi F. – volume: 51 start-page: 691 issue: 4 year: 1999 ident: e_1_2_11_1_25_1 article-title: Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors publication-title: Pharmacological Reviews contributor: fullname: Drummond D. C. – ident: e_1_2_11_1_13_1 doi: 10.1038/nature10144 – ident: e_1_2_11_1_29_1 doi: 10.1517/17425247.5.1.25 – ident: e_1_2_11_1_33_1 doi: 10.1016/S0169-409X(97)00083-5 – ident: e_1_2_11_1_76_1 doi: 10.1007/s11172-010-0390-y – ident: e_1_2_11_1_72_1 doi: 10.1111/j.1476-5381.2009.00112.x – ident: e_1_2_11_1_93_1 doi: 10.1007/s11095-010-0184-9 – ident: e_1_2_11_1_100_1 doi: 10.1016/j.ejpb.2010.01.002 |
| SSID | ssj0009933 |
| Score | 2.4560916 |
| SecondaryResourceType | review_article |
| Snippet | A number of antiangiogenic drugs have been approved by the Food and Drug Administration which are used in cancer therapy, and variety of other agents in... Abstract A number of antiangiogenic drugs have been approved by the Food and Drug Administration which are used in cancer therapy, and variety of other agents... |
| SourceID | proquest crossref pubmed wiley |
| SourceType | Aggregation Database Index Database Publisher |
| StartPage | 14721 |
| SubjectTerms | Angiogenesis inhibitors antiangiogenesis Antiangiogenic agents Antiangiogenics Bioavailability Cancer Cancer therapies combretastatin A4 Drug development Formulations Liposomes Metabolism Metastases Migration nanoliposome Side effects Therapy Tumors |
| Title | Targeted‐nanoliposomal combretastatin A4 (CA‐4) as an efficient antivascular candidate in the metastatic cancer treatment |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fjcp.28230 https://www.ncbi.nlm.nih.gov/pubmed/30697744 https://www.proquest.com/docview/2229850961 https://search.proquest.com/docview/2179522282 |
| Volume | 234 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1fSxwxEB9EEHzpH7XtWi2xSLEPe-5ukr1bfDqOiggtpSj4UFiSbAK2Xvbw7h4sFPoR_Iz9JJ3J_hFbCuI-7ZJks5vMTCaZmd8A7CdVWnG8YmW5iUVWGUrkbuJcjNywUEIXmiy6Hz_lJ-fi9EJerMBRFwvT4EP0B27EGUFeE4MrPT-8Aw39ZmaDjMxEKH8JSI8Uoi930FFFm0Y-uCBIkXaoQkl22Le8vxb9o2De11fDgnP8FL52n9r4mXwfLBd6YH78heL4yH95Bk9aRZSNG8p5DivWb8Dm2OMmfHrD3rHgGhrO3DdgrclYebMJP8-C57itfv-69crXV5ezel5P8UXYpSbfRYpQuvRsLNjBZIy1xHum5kx5ZgNYBa5x-EA51RoPWGYoroaOHRi2Qm2UTbuXGCoz9pr1zvBbcH784WxyErcZHGLDJU9iLfmQp3rInTWOjDwu1dVQIec7OdKp1TqvMqfyxGRJoQjeTEjntCp4ilRiOX8Bq7729hWwnEL2LUoMbitRWV3kSuECL5VUqVOFjOBtN5flrAHqKBtI5qzE4S3D8Eaw081y2fLqvKSM5iNCwUkj2OuLkcvIdKK8rZdYB-WWpMOyLIKXDXX0veCmi5RoEcFBmOP_d1-eTj6Hm-2HV30N66ijtW5tO7C6uF7aXdSDFvpNIPg_95cF3Q |
| link.rule.ids | 315,786,790,1382,27955,27956,46327,46751 |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VIgSXFloeKQUMQqgcsk1iO7uRuKwWqqW0FUJbqZcqsh1bKrDJqrt7KBISP6G_kV_CjPOoCkJC5JTIdpzYHs94Ht8AvIyKuOB4hcpyE4qkMJTI3YSpGLh-poTONFl0D4_S8bHYP5EnK_CmjYWp8SE6hRtRht-vicBJIb17hRr62cx6CdmJbsBNJHdJZPn20xV4VNYkkvdOCFLELa5QlOx2Ta9zoz9EzOsSq2c5e-tw2n5s7Wnypbdc6J759huO4__-zV1Ya2RRNqwXzz1YseUGbA5LPIdPL9gr5r1Dvdp9A27VSSsvNuH7xDuP2-Lnj8tSldXXs1k1r6b4IuxTk_siBSmdlWwo2M5oiLXEa6bmTJXMerwKZHP4QGnVaidYZii0hjQPDFuhQMqm7UsMlRl7zjp_-PtwvPduMhqHTRKH0HDJo1BL3uex7nNnjSM7j4t10VdI_E4OdGy1TovEqTQySZQpQjgT0jmtMh7jQrGcP4DVsirtI2ApRe1b3DS4LURhdZYqhTxeKqlipzIZwIt2MvNZjdWR16jMSY7Dm_vhDWC7nea8Idd5TknNBwSEEwfwvCtGQiPriSpttcQ6uHVJ0pclATysl0fXC567SI4WAez4Sf579_n-6KO_2fr3qs_g9nhyeJAfvD_68BjuoMjWeLltw-rifGmfoFi00E_96v8FTegJ_Q |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VIhAXCi2PQAGDECqHbJPYzm7EabVlVQpUFWqlHipFtmNLbdlk1d09FAmJn9Df2F_SGedRFYSEyCmR7TixPZ7xPL4BeBsVccHxCpXlJhRJYSiRuwlTMXD9TAmdabLoft1Ntw_EzqE8XIIPbSxMjQ_RKdyIMvx-TQQ-LdzmNWjoiZn2EjIT3YLbIuUJnby2vl1jR2VNHnnvgyBF3MIKRclm1_QmM_pDwrwpsHqOM16Bo_Zba0eT095irnvmx28wjv_5Mw_gfiOJsmG9dB7Cki1XYW1Y4il8cs7eMe8b6pXuq3CnTll5vgY_973ruC0uf12Uqqy-H0-rWTXBF2GXmpwXKUTpuGRDwTZGQ6wl3jM1Y6pk1qNVIJPDB0qqVrvAMkOBNaR3YNgKxVE2aV9iqMzYM9Z5wz-Cg_HH_dF22KRwCA2XPAq15H0e6z531jiy8rhYF32FpO_kQMdW67RInEojk0SZInwzIZ3TKuMxLhPL-WNYLqvSPgWWUsy-xS2D20IUVmepUsjhpZIqdiqTAbxp5zKf1kgdeY3JnOQ4vLkf3gDW21nOG2Kd5ZTSfEAwOHEAr7tiJDOynajSVgusgxuXJG1ZEsCTenV0veCpi6RoEcCGn-O_d5_vjPb8zbN_r_oK7u5tjfMvn3Y_P4d7KK81Lm7rsDw_W9gXKBPN9Uu_9q8AM-kIrA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Targeted%E2%80%90nanoliposomal+combretastatin+A4+%28CA%E2%80%904%29+as+an+efficient+antivascular+candidate+in+the+metastatic+cancer+treatment&rft.jtitle=Journal+of+cellular+physiology&rft.au=Nik%2C+Maryam+Ebrahimi&rft.au=Momtazi%E2%80%90Borojeni%2C+Amir+Abbas&rft.au=Zamani%2C+Parvin&rft.au=Navashenaq%2C+Jamshid+Gholizadeh&rft.date=2019-09-01&rft.issn=0021-9541&rft.eissn=1097-4652&rft.volume=234&rft.issue=9&rft.spage=14721&rft.epage=14733&rft_id=info:doi/10.1002%2Fjcp.28230&rft.externalDBID=n%2Fa&rft.externalDocID=10_1002_jcp_28230 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0021-9541&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0021-9541&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0021-9541&client=summon |